AR012964A1 - Compuetos derivados de bencimidazol, composiciones farmaceuticas que los contienen y su uso en la manufactura de medicamentos para tratar infeccionesvirales - Google Patents

Compuetos derivados de bencimidazol, composiciones farmaceuticas que los contienen y su uso en la manufactura de medicamentos para tratar infeccionesvirales

Info

Publication number
AR012964A1
AR012964A1 ARP980102756A ARP980102756A AR012964A1 AR 012964 A1 AR012964 A1 AR 012964A1 AR P980102756 A ARP980102756 A AR P980102756A AR P980102756 A ARP980102756 A AR P980102756A AR 012964 A1 AR012964 A1 AR 012964A1
Authority
AR
Argentina
Prior art keywords
8alkyl
hydrogen
alkyl
halo
hydroxy
Prior art date
Application number
ARP980102756A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9711982.0A external-priority patent/GB9711982D0/en
Priority claimed from GBGB9714552.8A external-priority patent/GB9714552D0/en
Application filed by Glaxo Group Ltd, Univ Michigan filed Critical Glaxo Group Ltd
Publication of AR012964A1 publication Critical patent/AR012964A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052Imidazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen a ciertos derivados de bencimidazol y su uso en la preparacion de medicamentos para la terapia médica, particularmente para el tratamiento oprofilaxis de infecciones virales tal como aquellas provocadas por el virus del herpes. Se describe a la preparacion de los derivados de bencimidazol yformulaciones farmacéuticas que los contienen. En particular, se proporciona compuestos de la formula (I) en donde Z es un sustituyente de la formula (Ia),(Ib) o (Ic) y R1 es halogeno hidroxi,azido, C1-8 alquilo, C1-8alcoxi, C2-6alquenilo, C2-6alquinilo, C6-14arilC2-6alquenilo, C6-14arilC2-6alquinilo,o -NR19R20 (en donde R19 y R20 pueden ser los mismos o diferentes y son hidrogeno, C1-8alquilo, cianoC1-8alquilo, hidroxiC1-8alquilo, haloC1-8alquilo,C3-7cicloalquilo, C1-8alquilC3-7cicloalquilo, C2-6alquenilo, C3-7cicloalquilC1-8alquilo, C2-6alquinilo, C6-14arilo, C6-14arilC1-6alquilo,heterocicloC1-8alquilo, C1-8alquilcarbonilo, C6-14arilsulfonilo, oR19 R20 junto con el átomo N al cual están unidos forman un anillo heterocíclico de 3,4, 5 o 6 miembros, OR21 (donde R21 es hidrogeno, C1-8alquilo, C3-7cicloalquilo , o C6-14arilo), o SR22 (en donde R22 es hidrogeno, C1-8 alquilo, hidroxi C1-8alquilo, C3-7 cicloalquilo, o C6-14 arilo); R2 es hidrogeno o halogeno; R3 y R4 pueden ser los mismos o diferentes y hidrogeno, halogeno, C1-8alquilo, C6-14arilo, heterociclo C6-14 arilo, C1-8 alcoxi, halo C1-8 alquilo o -SR24 (en donde R24 eshidrogeno, C1-8 alquilo, C6-14 arilo, o C6-14 aril C1-8 alquilo);R5 es hidrogeno, C1-8 alquilo, halo C1-8 alquilo o C1-8 alcoxi; R6 es hidrogeno, C1-8 alquilo, hidroxi C1-8 alquilo, halo C1-8 alquilo o C1-8alcoxi; R7 es hidrogeno, hidroxi,halogeno, C1-8 alquilo, hidroxi C1-8 alquilo, halo C1-8 alquilo, C1-8 alcoxi, o R6 y R7 forman conjuntamente una ceonta o
ARP980102756A 1997-06-10 1998-06-10 Compuetos derivados de bencimidazol, composiciones farmaceuticas que los contienen y su uso en la manufactura de medicamentos para tratar infeccionesvirales AR012964A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711982.0A GB9711982D0 (en) 1997-06-10 1997-06-10 Benzimidazole derivatives
GBGB9714552.8A GB9714552D0 (en) 1997-07-11 1997-07-11 Benzimidazole derivatives

Publications (1)

Publication Number Publication Date
AR012964A1 true AR012964A1 (es) 2000-11-22

Family

ID=26311687

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102756A AR012964A1 (es) 1997-06-10 1998-06-10 Compuetos derivados de bencimidazol, composiciones farmaceuticas que los contienen y su uso en la manufactura de medicamentos para tratar infeccionesvirales

Country Status (35)

Country Link
US (1) US6455507B1 (es)
EP (1) EP0994890B1 (es)
JP (1) JP4548866B2 (es)
KR (1) KR20010020465A (es)
CN (1) CN1265665A (es)
AP (1) AP1262A (es)
AR (1) AR012964A1 (es)
AT (1) ATE246700T1 (es)
AU (1) AU740792C (es)
BR (1) BR9810745A (es)
CA (1) CA2293470C (es)
CO (1) CO4970737A1 (es)
DE (1) DE69816992T2 (es)
DK (1) DK0994890T3 (es)
EA (1) EA002305B1 (es)
EE (1) EE9900564A (es)
ES (1) ES2205527T3 (es)
HK (1) HK1024921A1 (es)
HR (1) HRP980303B1 (es)
HU (1) HUP0002224A3 (es)
ID (1) ID24054A (es)
IL (1) IL133285A0 (es)
IS (1) IS5285A (es)
MA (1) MA26504A1 (es)
MY (1) MY132872A (es)
NO (1) NO314847B1 (es)
NZ (1) NZ501415A (es)
OA (1) OA11230A (es)
PE (1) PE84099A1 (es)
PL (1) PL337773A1 (es)
PT (1) PT994890E (es)
SK (1) SK171499A3 (es)
TR (1) TR199903053T2 (es)
TW (1) TW565566B (es)
WO (1) WO1998056761A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199801431T2 (xx) 1996-01-23 1998-10-21 The Regents Of The University Of Michigan Antiviral aktif maddeler olarak de�i�tirilmi� benzimidazol n�kleosidler.
PL338454A1 (en) 1997-07-30 2000-11-06 Univ Michigan Lixofuranosilbenzimidazoles as antiviral agents
DE19741715A1 (de) * 1997-09-22 1999-03-25 Hoechst Ag Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
GB0008939D0 (en) * 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
ATE369853T1 (de) 2001-03-12 2007-09-15 Avanir Pharmaceuticals Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
EA011515B1 (ru) * 2003-08-01 2009-04-28 Янссен Фармацевтика Н.В. Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
WO2005049582A1 (en) * 2003-11-14 2005-06-02 Auspex Pharmaceuticals, Inc. Method of preparation of novel nucleoside analogs and uses
MX2007010272A (es) * 2005-02-22 2008-03-12 Univ Michigan Inhibidores de moleculas pequenas de mdm2 y usos de los mismos.
DE102005019549A1 (de) * 2005-04-25 2006-12-14 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Diaminobenzimidazol
US7989422B2 (en) * 2005-12-22 2011-08-02 Alchemia Limited Antibacterial agents
US9889156B2 (en) 2006-01-19 2018-02-13 The Regents Of The University Of Michigan Method for treating noise-induced hearing loss (NIHL)
US9770433B2 (en) 2006-01-19 2017-09-26 The Regents Of The University Of Michigan Composition and method for treating tinnitus
US7951845B2 (en) 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
USRE46372E1 (en) 2006-01-19 2017-04-25 The Regents Of The Univerity Of Michigan Method for treating hearing loss
US10238599B2 (en) 2006-01-19 2019-03-26 The Regents Of The University Of Michigan Composition and method for treating congenital cytomegalovirus induced hearing loss
US8927528B2 (en) 2006-01-19 2015-01-06 The Regents Of The University Of Michigan Composition for treating hearing loss
US8338397B2 (en) 2006-01-19 2012-12-25 The Regents Of The University Of Michigan Composition and method of treating side effects from antibiotic treatment
US9919008B2 (en) 2006-01-19 2018-03-20 The Regents Of The University Of Michigan Method for treating age-related hearing loss (ARHL)
WO2009023855A2 (en) * 2007-08-15 2009-02-19 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
WO2009100045A1 (en) * 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2010036613A1 (en) 2008-09-26 2010-04-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051176A1 (en) 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
WO2010091308A2 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
WO2010090969A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CN103154014B (zh) 2010-04-28 2015-03-25 Isis制药公司 修饰核苷、其类似物以及由它们制备的寡聚化合物
US8546344B2 (en) 2010-10-28 2013-10-01 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl)-1H-benzimidazole
WO2014134493A1 (en) * 2013-03-01 2014-09-04 Los Alamos National Security, Llc Broad spectrum antibiotic compounds and use thereof
EP3137476B1 (en) 2014-04-28 2019-10-09 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
US10077242B2 (en) * 2014-12-01 2018-09-18 Virginia Commonwealth University Convergent approach to the total synthesis of telmisartan via a suzuki cross-coupling reaction
RU2629670C2 (ru) * 2016-08-04 2017-08-31 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) 2-Амино-5,6-дифтор-1-(бета-D-рибофуранозил)-бензимидазол, способ получения и противовирусная активность его в отношении вируса герпеса простого 1-го типа
KR102583547B1 (ko) 2020-03-30 2023-10-06 (주)바이오메트릭스 테크놀로지 신규한 벤지미다졸 유도체, 이의 제조방법 및 이의 항암제 용도
EP3907230B1 (en) 2020-03-30 2024-08-28 Biometrix Technology Inc. Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent comprising the same
KR102449266B1 (ko) 2020-06-23 2022-09-30 (주)바이오메트릭스 테크놀로지 항암 활성 그리고 항바이러스 활성을 갖는 신규한 벤지미다졸-탄수화물 결합체 화합물(Benzimidazole carbohydrate conjugate compound) 및 이의 제조 방법
US12043644B2 (en) 2020-06-23 2024-07-23 Biometrix Technology Inc Benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same
KR102342313B1 (ko) 2021-08-27 2021-12-24 (주)바이오메트릭스 테크놀로지 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1491244A (fr) 1966-03-09 1967-08-11 Nouveaux benzimidazoles solubles
FR1476350A (fr) 1966-04-18 1967-04-07 Yale & Towne G M B H Ferme-porte automatique à frein
US3655901A (en) 1970-07-30 1972-04-11 Merck & Co Inc Method of inhibiting the formation of phenylethanalamine-n-methyl transferase with 2-aminobenzimidazoles
DE2130030A1 (de) 1971-06-18 1972-12-21 Bayer Ag Fungizide und bakterizide Mittel
ES8101067A1 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
EP0304624A3 (de) 1987-07-29 1989-03-22 F. Hoffmann-La Roche Ag Benzimidazol-2-yl-pyridiniumverbindungen
IT1226100B (it) 1988-07-07 1990-12-10 Dompe Farmaceutici Spa Derivati benzimidazolici farmacologicamente attivi.
US5248672A (en) 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
EP0521463A3 (en) 1991-07-04 1993-04-14 Hoechst Aktiengesellschaft Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
GB9205071D0 (en) 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides
WO1994008456A1 (en) 1992-10-21 1994-04-28 The Regents Of The University Of Michigan Polysubstituted benzimidazoles as antiviral agents
US5399580A (en) 1993-03-08 1995-03-21 Burroughs Wellcome Co. Therapeutic nucleosides-uses
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides

Also Published As

Publication number Publication date
ES2205527T3 (es) 2004-05-01
HK1024921A1 (en) 2000-10-27
NO996086L (no) 2000-02-09
PE84099A1 (es) 1999-09-24
HRP980303A2 (en) 1999-04-30
EP0994890B1 (en) 2003-08-06
WO1998056761A2 (en) 1998-12-17
SK171499A3 (en) 2000-08-14
PT994890E (pt) 2003-11-28
CA2293470A1 (en) 1998-12-17
HUP0002224A1 (hu) 2001-04-28
JP2002504105A (ja) 2002-02-05
PL337773A1 (en) 2000-09-11
DE69816992T2 (de) 2004-07-22
NO996086D0 (no) 1999-12-09
AU740792C (en) 2003-01-23
AP1262A (en) 2004-03-16
OA11230A (en) 2003-07-09
EE9900564A (et) 2000-06-15
HUP0002224A3 (en) 2003-05-28
NZ501415A (en) 2001-10-26
KR20010020465A (ko) 2001-03-15
BR9810745A (pt) 2001-03-13
TR199903053T2 (xx) 2000-11-21
CA2293470C (en) 2008-05-13
EA199901031A1 (ru) 2000-06-26
JP4548866B2 (ja) 2010-09-22
AU740792B2 (en) 2001-11-15
EA002305B1 (ru) 2002-02-28
AU8536098A (en) 1998-12-30
IS5285A (is) 1999-12-06
DK0994890T3 (da) 2003-12-01
EP0994890A2 (en) 2000-04-26
ID24054A (id) 2000-07-06
US20020094963A1 (en) 2002-07-18
IL133285A0 (en) 2001-04-30
US6455507B1 (en) 2002-09-24
HRP980303B1 (en) 2002-08-31
TW565566B (en) 2003-12-11
MA26504A1 (fr) 2004-12-20
CO4970737A1 (es) 2000-11-07
MY132872A (en) 2007-10-31
DE69816992D1 (en) 2003-09-11
CN1265665A (zh) 2000-09-06
WO1998056761A3 (en) 1999-04-15
NO314847B1 (no) 2003-06-02
AP9901707A0 (en) 1999-12-31
ATE246700T1 (de) 2003-08-15

Similar Documents

Publication Publication Date Title
AR012964A1 (es) Compuetos derivados de bencimidazol, composiciones farmaceuticas que los contienen y su uso en la manufactura de medicamentos para tratar infeccionesvirales
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
DK44791D0 (da) Behandling af beskadiget knoglemarv
TW200626153A (en) Heterocyclic derivatives and their use as therapeutic agents
AR070473A2 (es) Compuestos inhibidores de la renina, un procedimiento de preparacion del compuesto, una composicion farmaceutica, uso del compuesto para preparar un medicamento y compuesto intermediario
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626154A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200624427A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626139A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
ATE73815T1 (de) Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten.
BR0015605A (pt) Composição e uso
TW200626155A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
AR019305A1 (es) Hiv y tratamiento viral.
AR043367A2 (es) Derivados de benzofenona, composiciones farmaceuticas y procesos de preparacion.
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
UY25857A1 (es) 4-alquenil (y alquinil) oxindoles los cuales inhiben las quinasas dependientes de ciclina (cdks)
AR045040A1 (es) Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos
AR032778A1 (es) Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamento
BR9910179A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para tratar uma doença ou condição mediada por fator xa em um animal de sangue quente
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
DE69312567D1 (de) 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel

Legal Events

Date Code Title Description
FA Abandonment or withdrawal